Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00239577 · ClinicalTrials.gov registry record · Phase 2
A Trial of a Walter Reed Army Institute of Research (WRAIR) Live Attenuated Virus Tetravalent Dengue Vaccine in Healthy US Adults
A Phase 2 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 2
- Development phase
- 86
- Enrollment target
NCT00239577 is a Phase 2 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 86 participants.
The verdict
NCT00239577, a Phase 2 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 86 participants
- Enrollment target
Study Summary
This descriptive study will evaluate the safety and immunogenicity of 5 different formulations of the WRAIR dengue vaccine compared to a placebo.
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL Live attenuated tetravalent dengue vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 86 participants |
| Start Date | 2006-04-05 |
| Est. Completion | 2007-06-19 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00239577
The ClinicalTrials.gov registry entry for NCT00239577 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 86 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00239577 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00239577 about?
NCT00239577 is a clinical study titled "A Trial of a Walter Reed Army Institute of Research (WRAIR) Live Attenuated Virus Tetravalent Dengue Vaccine in Healthy US Adults". This descriptive study will evaluate the safety and immunogenicity of 5 different formulations of the WRAIR dengue vaccine compared to a placebo.
What is the current status of trial NCT00239577?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 86 participants. The study started on 2006-04-05. Estimated completion is 2007-06-19.
What interventions are being tested in trial NCT00239577?
The interventions under investigation include: Placebo (BIOLOGICAL), Live attenuated tetravalent dengue vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00239577?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.